It is in the trial data, and you are not imagining it.
In the phase 2 trial, cutaneous hyperesthesia and skin sensitivity were reported by 7% of people on retatrutide against 1% on placebo. It rose with dose, reaching 13 to 14% in the highest arms. None of the events were severe or serious, none led to anyone stopping, and none came with anything visible on the skin.1
That last detail is why people doubt themselves. Your skin looks completely normal and feels like sandpaper, or burns under a shirt seam, or cannot tolerate a shower at the temperature you have used for years.
The raised resting heart rate is in the same trial. The dry mouth and the sulfur burps are class effects. All four are documented, and the one nobody should ignore is the heart rate.
Is it allodynia?
Probably not in the strict sense. The distinction matters if you are going to describe this to a doctor.
Allodynia is pain from something that should not hurt at all: a bedsheet, a light breeze.
Hyperesthesia is ordinary sensation turned up too high. Touch registers as more intense than it should.
Dysesthesia is sensation that is unpleasant or wrong in quality: burning, tingling, crawling, sandpaper.
The trial used the terms hyperesthesia and skin sensitivity, and the phase 3 programme has reported dysesthesia. What people describe on forums, sandpaper skin, burning, tingling, itching that has nothing to scratch, is usually dysesthesia or hyperesthesia rather than true allodynia, though the line blurs in practice.
Say "abnormal skin sensation" and describe what it actually feels like. That gets you further than a label a clinician may disagree with.
How common is it, and does the dose matter?
The same table answers both, and the dose answer is clear.
| Retatrutide dose | Hyperesthesia or related event |
|---|---|
| Placebo | 1% |
| 1 mg | 1% |
| 4 mg (2 mg start) | 6% |
| 4 mg | 6% |
| 8 mg (2 mg start) | 3% |
| 8 mg (4 mg start) | 14% |
| 12 mg | 13% |
| All retatrutide | 6% |
From the phase 2 trial, 338 participants over 48 weeks.1
Overall, the paper reports cutaneous hyperesthesia and skin sensitivity events in 7% of retatrutide participants against 1% on placebo, with the dose relationship visible in the arms above.
Two things follow. At the doses people buy, which are often at the top of that range or above it, the rate in the trial was roughly one in seven. And nothing in that table was severe, serious or a reason anyone stopped.
Why does my skin look completely normal?
Because the effect is in the nerves, not the skin. The single most useful line in the paper: none of these events were associated with overt skin findings.1
There is no rash to point at, no redness, no dryness that explains it. The sensation is neurological rather than dermatological, which is why moisturiser does nothing and why a partner looking at your arm sees nothing wrong.
It is also why people get dismissed. A symptom with no visible sign, reported by someone taking an unapproved compound bought online, is easy to wave away. The trial data is the answer to that, and it is worth having the citation ready.
Does retatrutide raise your resting heart rate?
Yes, and the same trial documented the pattern.
Heart rate increased in a dose-dependent way with retatrutide up to 24 weeks and then declined thereafter.1 So the rise is real, it tracks the dose, and in the trial it was not permanent.
This is the symptom on your list that deserves attention rather than reassurance. A resting heart rate that has climbed by a few beats is an expected class effect. One that has climbed substantially, or comes with palpitations, breathlessness, chest discomfort or feeling faint, is a reason to stop and be seen rather than to search for reassurance.
Worth knowing what your baseline was. A number means little without the number it replaced, which our bloodwork guide makes the same point about.
Why the dry mouth and the sulfur burps?
These two are the least interesting on your list, because both have ordinary explanations.
Dry mouth usually tracks fluid balance. Eating much less means drinking much less, since food carries a substantial share of daily water, and these drugs slow everything down. Our dehydration guide covers the path from there to something that matters.
Sulfur burps are eructation, a labelled effect of this drug class: 4 to 5% on tirzepatide against 1% on placebo. Food sitting longer in the stomach is the plausible mechanism. It is unpleasant, not dangerous, and it eases at a steady dose.
Neither is a reason to stop. Both are reasons to drink more than feels necessary.
Why forums and clinicians disagree about this
Ask in a subreddit and the answer is yes, everyone gets it. Ask a doctor unfamiliar with the compound and you may be told it is not a known effect.
Both responses have a basis. The forum answer is right that it is real and common, and wrong that it is universal, since the trial puts it at roughly one in seven at higher doses. The clinical answer reflects the fact that retatrutide has no label, no approval and no package insert to consult, so there is nothing for a clinician to look it up in.
The thing that settles it is the published trial, and it is open to anyone: Jastreboff and colleagues, New England Journal of Medicine, 2023. Bringing the citation is more useful than bringing the forum thread.
Why would a weight-loss drug do this to your skin?
Nobody knows, and the honest version of that answer has three candidate explanations rather than none.
The drug itself, by some direct mechanism. Retatrutide acts on three receptors, including the glucagon receptor, which the other drugs in this class do not touch. Whether any of that reaches peripheral nerves is unstudied. The trial recorded the effect without explaining it.
Rapid metabolic change. In diabetes care there is a recognised phenomenon with a name: treatment-induced neuropathy of diabetes, historically called insulin neuritis. Correcting long-standing high blood glucose too quickly can produce an acute, painful small-fibre neuropathy within weeks, and the largest series of it was published in Brain in 2015.3 It is counterintuitive, it is real, and the standard advice that follows from it is to improve glucose control gradually.
Nobody has looked at whether rapid weight loss on an incretin does anything comparable, and retatrutide trial participants were not people correcting years of untreated hyperglycaemia. So this is an analogy rather than an explanation. It is worth knowing because it establishes that fast metabolic improvement can itself provoke nerve symptoms, which is not an obvious idea.
Eating much less. Thiamine and B12 both matter for nerve function, and a sharp sustained drop in food intake is a plausible route to being short of either. That is testable with a blood test, unlike the other two, which is a reason to mention it to a doctor.
What makes the first explanation most likely is the dose relationship in the trial table. A nutrient or glucose effect would not track the dose that neatly. But that is reasoning from a pattern, not a finding, and the paper offers no mechanism at all.
Is it even retatrutide?
The question this site exists to ask, and it is not rhetorical here.
The trial tells you what pharmaceutical retatrutide did to 338 people under supervision. It tells you nothing about the vial on your counter. Retatrutide is approved nowhere, so every vial in circulation came from the grey market.
In our September capture, 336 listings across 105 sellers carry it, and 205 of those listings across 58 sellers use a code or abbreviation rather than the name, GLP-3 and its variants among them.2 Our decoder guide covers what those codes mean and how often they are wrong.
So two readers with identical symptoms can be in completely different situations: one experiencing a documented effect of the compound, the other reacting to something else in the vial. Nothing in the symptom itself distinguishes them.
What the trial does establish is that this symptom is not evidence of a bad vial. It happens with the real thing, at a known rate, in a controlled setting.
When to stop and be seen
Most of this list is tolerable. These are not.
Skin sensation that becomes genuinely painful, spreads, or comes with weakness or numbness, which points at something other than this. A resting heart rate that has risen substantially, or any palpitations, chest discomfort, breathlessness or faintness. Severe abdominal pain, especially going through to the back. Vomiting you cannot stop, or passing very little urine.
And the one people skip: if you are having surgery or any procedure with sedation, say what you are taking, whatever it is and wherever it came from.
Common questions
Is skin sensitivity a known side effect of retatrutide?
Yes. The phase 2 trial reported cutaneous hyperesthesia and skin sensitivity in 7% of retatrutide participants against 1% on placebo, rising with dose to 13 to 14% in the highest arms. None were severe or serious.
Is it allodynia?
Usually not in the strict sense. Allodynia means pain from something that should not hurt at all. What most people describe is hyperesthesia, ordinary sensation turned up too high, or dysesthesia, sensation that feels wrong in quality. Describe the feeling rather than naming it.
Why does my skin look completely normal?
Because the effect is neurological rather than dermatological. The trial specifically notes that none of these events came with visible skin findings, which is why creams do nothing and why it is easy to be dismissed.
Does it go away?
In the trial none of these events led anyone to stop treatment, and none was severe. Beyond that the published data does not say how long they lasted. The dose relationship suggests a lower dose means less of it.
Does retatrutide raise your heart rate?
Yes, dose-dependently, up to 24 weeks in the phase 2 trial, declining after that. A few beats is expected. A substantial rise, or palpitations, breathlessness or chest discomfort, is a reason to stop and be seen.
Why do I have sulfur burps?
Eructation is a labelled effect of this drug class, at 4 to 5% on tirzepatide against 1% on placebo, and the plausible mechanism is food moving more slowly through the stomach. It eases once the dose stops moving.
Why is my mouth so dry?
Usually fluid balance. Eating much less means drinking much less, because food carries a substantial share of daily water intake.
Does this mean my vial is fake?
No. The symptom appears in the trial of pharmaceutical retatrutide at a known rate, so it is not evidence either way about what you are holding. In our capture, 336 listings across 105 sellers carry retatrutide and most use a code rather than the name, which is a separate problem from this one.
Could it be a vitamin deficiency?
Possible and worth testing, since thiamine and B12 both matter for nerve function and intake drops sharply on these drugs. It is the only one of the plausible explanations you can check with a blood test, which is a reason to raise it.
My doctor says this is not a known side effect. What do I say?
That it appears in the published phase 2 trial in the New England Journal of Medicine, at 7% against 1% on placebo. Retatrutide has no label for anyone to consult, which is why it is easy to miss.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine 2023;389:514-526. doi:10.1056/NEJMoa2301972. Phase 2, multicentre, randomised, double-blind, placebo-controlled trial, 338 adults, 48 weeks of weekly subcutaneous retatrutide. Cutaneous hyperesthesia and skin sensitivity adverse events were reported in 7% of participants receiving retatrutide against 1% on placebo; none were severe or serious, none were associated with overt skin findings, and none led to discontinuation. The hyperesthesia row of Table 3 gives 1% on placebo and 1%, 6%, 6%, 3%, 14% and 13% across the retatrutide arms, 6% overall. Heart rate increased in a dose-dependent manner up to 24 weeks and declined thereafter. Serious adverse events occurred in 4% of both groups.
- Peptide Decoding vendor price capture, 29 September 2026. peptidedecoding.com/prices. Our own data, counting one priced product at one seller as a listing: 7,534 listings across 151 sellers. Retatrutide appears in 336 listings across 105 sellers, of which 205 listings across 58 sellers use a code or abbreviation in the product name rather than the compound name.
- Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015;138(1):43-52. doi:10.1093/brain/awu307. The largest series describing the phenomenon, read via the published abstract and subsequent reviews citing it. Acute painful small-fibre and autonomic neuropathy following rapid correction of chronic hyperglycaemia, historically termed insulin neuritis, detected in up to 10% of patients referred for evaluation of diabetic neuropathy at a tertiary centre. Cited here as an established precedent that rapid metabolic improvement can provoke nerve symptoms, not as an explanation of the retatrutide finding, which has not been studied.
Citing this page. Peptide Decoding. Skin Like Sandpaper on Retatrutide: Is That Normal? Figures from the phase 2 trial, NEJM 2023. https://peptidedecoding.com/guides/retatrutide-skin-sensitivity